

# References

1. Santé publique France (SPF). Augmentation des infections à *Mycoplasma pneumoniae* en France. Saint-Maurice cedex: SPF; 2023. Available at: <https://www.santepubliquefrance.fr/les-actualites/2023/augmentation-des-infections-a-mycoplasma-pneumoniae-en-france>
2. Karolinska Universitetslaboratoriet and Region Stockholm. Luftvägspatogener. Stockholm: Karolinska Universitetslaboratoriet and Region Stockholm; 2023. Available at: <https://www.karolinska.se/globalassets/global/2-funktioner/funktion-kul/klinisk-mikrobiologi/epidemiologi/rapport-influensa--och-rs-virus-och-andra-luftvagspatogener.pdf>
3. Folkehelseinstituttet (FHI). Ukerapporter om covid-19, influensa og andre luftveisinfeksjoner. Oslo: FHI; 2023. Available at: <https://www.fhi.no/publ/statusrapporter/luftveisinfeksjoner/>
4. Nederlands Instituut voor Onderzoek van de Gezondheidszorg (NIVEL). Cijfers ziekten per week - actueel: wat heerst er nu in Nederland? Utrecht: NIVEL; 2023. Available at: <https://www.nivel.nl/nl/resultaten-van-onderzoek/actuele-cijfers-ziekten-per-week>
5. (SSI) SSI. Der er epidemi med mycoplasma-infektioner - også kendt som kold lungebetændelse. Copenhagen: SSI; 2023. Available at: <https://www.ssi.dk/aktuelt/nyheder/2023/der-er-epidemi-med-mycoplasmainfektioner-ogsaa-kendt-som-kold-lungebetaendelse>
6. Centers for Disease Control and Prevention (CDC). Weekly U.S. Influenza Surveillance Report | CDC. Atlanta: @CDCgov; 2023. Available at: <https://www.cdc.gov/flu/weekly/index.htm>
7. Public Health Agency of Canada. Weekly influenza reports - Canada.ca. Ottawa: Government of Canada; 2023. Available at: <https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-influenza-reports.html>
8. Centers for Disease Control and Prevention (CDC). Pediatric Pneumonia Update | CDC. Atlanta: CDC; 2023. Available at: <https://www.cdc.gov/respiratory-viruses/whats-new/pediatric-pneumonia-update.html>
9. National Health Commission of China. 国家卫生健康委员会 2023 年 11 月 13 日新闻发布会文字实录. Beijing: NHC; 2023. Available at: <http://www.nhc.gov.cn/xcs/s3574/202311/0807e750e6cc4a81a22b6d881913cf5d.shtml>
10. National Health Commission of China. 国家卫生健康委员会 2023 年 12 月 10 日新闻发布会文字实录. Beijing: NHC; 2023. Available at: <http://www.nhc.gov.cn/xcs/s3574/202312/1d8f08ea280748bc8685333846ac308a.shtml>
11. Chinese Center for Disease Control and Prevention. 全国新型冠状病毒感染疫情情况. Beijing: Chinese CDC; 2023. Available at: [https://www.chinacdc.cn/jkzt/crb/zl/szkb\\_11803/jszl\\_13141/202312/t20231212\\_271320.html](https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202312/t20231212_271320.html)
12. 질병관리청. 마이코플라스마 폐렴 진료 현장점검과 보완책 마련을 위한 전문가-관계부처 합동 점검회의 개최(12.6.수). Seoul: Government of the Republic of Korea; 2023. Available at: <https://www.kdca.go.kr>
13. National Institute of Infectious Diseases. インフルエンザ Influenza. Tokyo: NIID; 2023. Available at: <https://www.niid.go.jp/niid/en/10/2096-weeklygraph/1644-01flu.html>
14. European Centre for Disease Prevention and Control (ECDC) and WHO Regional Office for Europe (WHO/Europe). Operational considerations for respiratory virus surveillance in Europe. Stockholm and Copenhagen: ECDC and WHO/Europe; 2022. Available at: <https://www.ecdc.europa.eu/en/publications-data/operational-considerations-respiratory-virus-surveillance-europe>
15. European Centre for Disease Prevention and Control (ECDC) and WHO Regional Office for Europe (WHO/Europe). European Respiratory Virus Surveillance Summary (ERVISS). Stockholm and Copenhagen: ECDC and WHO/Europe; 2023. Available at: <https://erviss.org/>
16. Brady M, Duffy R, Domegan L, Salmon A, Maharjan B, apos, et al. Establishing severe acute respiratory infection (SARI) surveillance in a sentinel hospital, Ireland, 2021 to 2022. Eurosurveillance. 2023;28(23):2200740. Available at: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.23.2200740>
17. EUROMOMO, Statens Serum Institut. EuroMOMO Bulletin, Week 48, 2023. Copenhagen: SSI; 2023. Available at: <https://euromomo.eu/dev-404-page/>
18. World Health Organisation. Updated working definitions and primary actions for SARS-CoV-2 variants. Geneva: WHO; 2023. Available at: <https://www.who.int/publications/m/item/updated-working-definitions-and-primary-actions-for--sars-cov-2-variants>
19. European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 01 December 2023. Stockholm: ECDC; 2023. Available at: <https://www.ecdc.europa.eu/en/covid-19/variants-concern>
20. World Health Organisation. Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. Geneva: WHO; 2023. Available at: <https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season>
21. Beeton ML, Zhang X-S, Uldum SA, Bébéar C, Dumke R, Gullsby K, et al. *Mycoplasma pneumoniae* infections, 11 countries in Europe and Israel, 2011 to 2016. Euro Surveill. 2020;25(2):1900112. Available at: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.2.1900112>
22. European Centre for Disease Prevention and Control (ECDC). Reporting Protocol for integrated respiratory virus surveillance, version 1.3. Stockholm: ECDC; 2023. Available at: <https://www.ecdc.europa.eu/en/publications-data/reporting-protocol-integrated-respiratory-virus-surveillance-version-13>
23. European Medicine Agency (EMA). Beyfortus - nirsevimab. Amsterdam: EMA; 2023. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus>

24. European Medicine Agency (EMA). First RSV vaccine to protect infants up to 6 months of age and older adults. Amsterdam: EMA; 2023. Available at: <https://www.ema.europa.eu/en/news/first-rsv-vaccine-protect-infants-6-months-age-and-older-adults>
25. European Centre for Disease Prevention and Control. ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants. Stockholm: ECDC; 2023. Available at: <https://www.ecdc.europa.eu/en/news-events/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants>
26. World Health Organisation. WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines. Geneva: WHO; 2023. Available at: <https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.1>
27. European Centre for Disease Prevention and Control (ECDC). Interim public health considerations for COVID-19 vaccination roll-out during 2023. Stockholm: ECDC; 2023. Available at: <https://www.ecdc.europa.eu/en/publications-data/interim-public-health-considerations-covid-19-vaccination-roll-out-during-2023>
28. Sciensano. Belgium COVID-19 Epidemiological Situation. Ixelles: Sciensano; 2023. Available at: [https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/p\\_j1f02pfnpc](https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/p_j1f02pfnpc)
29. Statens Serum Institute (SSI). Covid-19 - overvågning. Copenhagen: SSI; 2023. Available at: <https://www.ssi.dk/sygdomme-beredskab-og-forskning/sygdomsovervaagning/c/covid19-overvaagning>
30. Santé publique France. GÉODES -L'observatoire cartographique de Santé publique France. Saint Maurice: SPF; 2023. Available at: <https://geodes.santepubliquefrance.fr/#c=home>
31. National Institute for Public Health and the Environment (RIVM). Cijfers COVID-19 vaccinatieprogramma. Bilthoven: RIVM; 2023. Available at: <https://www.rivm.nl/corona/actueel/vaccinatiecijfers>
32. Folkehelseinstituttet (FHI). Eldre og risikogrupperne bør vaksinere seg nå! Oslo: FHI; 2023. Available at: <https://www.fhi.no/nyheter/2023/eldre-og-risikogrupperne-bor-vaksinere-seg-na/>
33. Folkhalsomyndigheten. Statistik för vaccination mot covid-19. Solna: Folkhalsomyndigheten; 2023. Available at: <https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-visualisering/vaccinationsstatistik/statistik-for-vaccination-mot-covid-19/>
34. European Centre for Disease Prevention and Control. Risk groups for severe influenza. Stockholm: ECDC; 2023. Available at: <https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/risk-groups>
35. European Centre for Disease Prevention and Control. Public health guidance: Seasonal influenza vaccination of children and pregnant women. Stockholm: ECDC; 2012. Available at: <https://www.ecdc.europa.eu/en/publications-data/public-health-guidance-seasonal-influenza-vaccination-children-and-pregnant-women>
36. European Centre for Disease Prevention and Control. Seasonal influenza vaccination recommendations and coverage rates in EU/EEA Member States. Stockholm: ECDC; 2023. Available at: <https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-recommendations-and-coverage-rates-eueea-member>
37. European Medicine Agency (EMA). Abrysvo - Respiratory syncytial virus vaccine (bivalent, recombinant). Amsterdam: EMA; 2023. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo>
38. European Medicine Agency (EMA). Arexvy - Recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E. Amsterdam: EMA; 2023. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy>
39. Bundesministerium für Soziales G, Pflege und Konsumentenschutz (BMSGPK),. Impfplan Österreich 2023/2024. Wien: BMSGPK; 2023. Available at: [https://www.sozialministerium.at/dam/jcr:eb64732e-1747-400a-beeb-6d069f781182/Impfplan\\_%C3%96sterreich\\_2023\\_2024\\_Version1.0.pdf](https://www.sozialministerium.at/dam/jcr:eb64732e-1747-400a-beeb-6d069f781182/Impfplan_%C3%96sterreich_2023_2024_Version1.0.pdf)
40. Superior Health Council (SHC). Vaccination against RSV (adults). Brussels: SHC; 2023. Available at: [https://www.shc.be/20230918\\_shc-9725\\_rsv\\_vaccination\\_adults\\_vweb\\_1.pdf](https://www.shc.be/20230918_shc-9725_rsv_vaccination_adults_vweb_1.pdf)
41. Folkhalsomyndigheten. Personer från 75 år rekommenderas vaccination mot RS-virus. Solna: Folkhalsomyndigheten; 2023. Available at: <https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2023/september/personer-fran-75-ar-rekommenderas-vaccination-mot-rs-virus/>
42. European Centre for Disease Prevention and Control (ECDC). Considerations for infection prevention and control in relation to respiratory viral infections in healthcare settings. Stockholm: ECDC; 2023. Available at: <https://www.ecdc.europa.eu/en/publications-data/considerations-infection-prevention-and-control-practices-relation-respiratory>
43. Haute Autorité de Santé. Nirsevimab (Beyfortus®) dans la prévention des bronchiolites à virus respiratoire syncytial (VRS) chez les nouveau-nés et les nourrissons. Saint Denis: HAS; 2023. Available at: [https://www.has-sante.fr/jcms/p\\_3461236/fr/nirsevimab-beyfortus-dans-la-prevention-des-bronchiolites-a-virus-respiratoire-syncytial-vrs-chez-les-nouveau-nes-et-les-nourrissons](https://www.has-sante.fr/jcms/p_3461236/fr/nirsevimab-beyfortus-dans-la-prevention-des-bronchiolites-a-virus-respiratoire-syncytial-vrs-chez-les-nouveau-nes-et-les-nourrissons)
44. Ministère de la Santé et de la Sécurité Sociale (MSSS). Nouvelle immunisation pour se protéger de la bronchiolite pour les nourrissons et jeunes enfants. Luxembourg: MSSS; 2023. Available at: <https://msss.gouvernement.lu/fr/actualites.gouvernement+fr+actualites+toutes+actualites+communiques+2023+09-septembre+22-immunisation-bronchiolite-nourrissons.html>
45. Ministerio de Sanidad. Recomendaciones de utilización de nirsevimab frente a virus respiratorio sincital para la temporada 2023-2024. Madrid: Ministerio de Sanidad; 2023. Available at: <https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/Nirsevimab.pdf>
46. European Medicine Agency (EMA). Synagis - palivizumab. Amsterdam: EMA; 2023. Available at:

---

<https://www.ema.europa.eu/en/medicines/human/EPAR/synagis>

47. European Centre for Disease Prevention and Control (ECDC). Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA. Stockholm: ECDC; 2021. Available at: <https://www.ecdc.europa.eu/en/publications-data/facilitating-covid-19-vaccination-acceptance-and-uptake>